{"id":"W2605009867","doi":"10.1158/1078-0432.ccr-16-2818","title":"A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Institutes of Health; American Association for Cancer Research","keywords":"Lenalidomide; Medicine; Internal medicine; Diffuse large B-cell lymphoma; Neutropenia; Clinical endpoint; Oncology; Rituximab; Thalidomide; Phases of clinical research; Febrile neutropenia; Gastroenterology; Surgery; Lymphoma; Multiple myeloma; Randomized controlled trial; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004075929,0.0002286073,0.001213809,0.000106351,0.000431374,0.0001396462,0.0007111565,0.00006275326,0.00004128037],"category_scores_gemma":[0.01118907,0.0001158614,0.00006843005,0.0002039774,0.0008563204,0.0001513487,0.000892966,0.0003724166,0.00001323767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003299768,"about_ca_system_score_gemma":0.0008274915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006343098,"about_ca_topic_score_gemma":0.005167111,"domain_scores_codex":[0.9957041,0.001408704,0.0009009148,0.0006480918,0.0008473349,0.0004909279],"domain_scores_gemma":[0.9892906,0.007989343,0.0003295303,0.001299337,0.0004446337,0.0006465695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4925516,0.1092664,0.3908052,0.00004267538,0.0002635954,0.00005271456,0.0004853334,1.850144e-7,0.00000246516,0.000005895207,0.0009725579,0.0055513],"study_design_scores_gemma":[0.6097587,0.006169539,0.3815717,0.0003573147,0.000161695,1.251079e-7,0.0002038763,0.00003866298,0.00003581564,0.000001069436,0.001616511,0.00008500413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896305,0.0003540467,5.026469e-7,0.001664065,0.0001936858,0.007865031,0.00008012475,0.000008815111,0.0002032247],"genre_scores_gemma":[0.9980468,0.0004016099,0.0000749613,0.0003910386,0.0001043653,0.0007398519,0.00001545464,0.00003207714,0.0001938515],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1172071,"threshold_uncertainty_score":0.9971401,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2495991745781395,"score_gpt":0.5288692121540582,"score_spread":0.2792700375759187,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}